{
  "trial_id": "NCT04160195",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "MALIGNANCY CRITERIA: Patients must have any B-cell lymphoma, or CLL/SLL, Gray-zone lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, or classical Hodgkin lymphoma with any CD19 or CD20 expression on Reed-Sternberg cells.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "DLBCL patients must have received at least two prior chemotherapy-containing regimens at least one of which must have contained doxorubicin and a monoclonal antibody.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients that require urgent therapy due to tumor mass effects or spinal cord compression.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "HIV-positive patients are excluded because HIV causes complicated immune deficiency and study treatment can pose more risks for these patients.",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of PCOS, Obesity, HTN, and has been diagnosed with Burkitt's lymphoma. They have received prior chemotherapy-containing regimens and have measurable malignancy.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT04160195",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}